New drugs for relapsed and refractory Hodgkin's lymphoma

Bookmark and Share
Published: 22 Jun 2012
Views: 4868
Prof Anas Younes - MD Anderson Cancer Center, Houston, USA

Prof Anas Younes talks to ecancer at the 17th European Haematology Association Congress in Amsterdam about a new class of monoclonal antibodies, mTOR inhibitors and the importance of clinical trials.


A trial using brentuximab vedotin, a new class of monoclonal antibodies that target CD30, showed 74% response and 30% complete response rate.


Patients with complete response had an average of 2 years without relapse; however, patients with partial response had a shorter remission period. Brentuximab vedotin, now FDA approved, is one of most active single agents and produces a high response rate with low toxicity.


Dr Younes also discusses everolimus, currently the only mTOR inhibitors only approved for non-Hodgkin’s and Hodgkin’s lymphoma, and ibrutinib and a PI3 kinase inhibitor, both oral with a broad activity in the relapse setting.


Filiming supported by Amgen